Not only is cystic fibrosis a devastating disease, most patients living with cystic fibrosis do not have access to an effective treatment. The results from clinical studies indicate that the addition of the new triple therapy will make treatment possible for around 90 percent of patients. The patient community is eager for this advance, and it is critical that ICER acknowledge that the value a broadly effective treatment creates for patients.
